DistillerSR is a web-based platform that allows researchers to collaborate concurrently on the same projects from anywhere, without blocking or overwriting one another. Bootstrapped since its formation in 2008, Evidence Partners pioneered the development of AI-enabled literature review software through the development of DistillerSR, which has had double-digit growth since the platform's launch in 2009. Literature reviews are the cornerstone of evidence-based research, but their production has traditionally been highly manual, time consuming, and error prone. Today, more than 300 of the world's leading research organizations, including more than 60 percent of the largest pharmaceutical and medical device companies, trust DistillerSR to securely produce transparent, audit-ready, and regulatory compliant literature reviews faster and more accurately than any other method. With more organizations using DistillerSR to automate their systematic reviews, healthcare researchers can make more informed and time-sensitive health policy decisions, clinical practice guidelines, regulatory submissions, and deliver better overall research.

Michelle Wu, cofounder and CEO and KK (Qiang Kou 寇强) tech cofounder at Nyquist Data, an AI powered ... [ ] cloud-based platform providing business, clinical, and regulatory intelligence and analytics for medical devices and pharmaceuticals companies How long does it take to get FDA approval for a heart-failure drug? It sounds like a simple question, but without the help of an artificial intelligence (AI) powered MedTech cloud-based platform, it could take months and millions of dollars to find out. The market size for AI in healthcare is projected to reach $187.95 billion by 2030, according to Precedence Research. When Michelle Wu was first asked this question, global clinical and regulatory healthcare information was publicly available, but it was scattered around the world in different databases and languages. Worse yet, keywords were misspelled or there were handwritten notes included in the databases, making what should be searchable unsearchable.

It seems to be in every other headline. There's no doubt AI has the potential to transform medical device manufacturing. Rather than focus on a complete transformation, manufacturers can see benefits by focusing on simply enhancing it. AI on a manufacturing line doesn't have to mean everything is automated and there are no humans involved. On the contrary, humans continue to be essential in manufacturing, even with AI.

GTC brought together dozens of healthcare innovators to present their work -- and announce new AI-accelerated applications and medical devices. More than 200,000 people registered for last week's online conference, where they attended hundreds of sessions spanning industries. The healthcare track included speakers from AstraZeneca, Mayo Clinic, Medtronic, Netherlands Cancer Institute and Pfizer, as well as more than 50 NVIDIA Inception startups. Here's some of the healthcare news shared at the show by NVIDIA, leading research institutions, and AI and medical device companies: Janssen, the pharmaceutical arm of Johnson & Johnson, shared its intelligent automation work using natural language processing models to scan medical literature that reports patients who may have experienced possible side effects. The latest version of the Janssen AI platform, which uses a customized version of BioMegatron using the NVIDIA NeMo framework, was set up in late 2021 to help accelerate the shortlisting of medical literature for human review to analyze drug safety.

Bob Tilling, VP global sales, Kallik, explains why medical device companies will have to embrace the digital world that lies ahead. Against this backdrop, medical device organisations have had to prepare themselves for compliance deadlines and adapt to new technologies. Looking ahead the busy period doesn't appear to be going away anytime soon. From this month, I expect to see a sharp rise in organisations feeling the pressure of the looming IVDR deadline in May 2022. Here, technology will again prove its worth, and it will be on standby to lend a digital hand to businesses yet to make progress towards reaching compliance.

Johnson & Johnson and GE are among the companies best positioned to take advantage of future artificial intelligence disruption in the medical devices industry, our analysis shows. The assessment comes from GlobalData's Thematic Research ecosystem, which ranks companies on a scale of one to five based on their likelihood to tackle challenges like artificial intelligence and emerge as long-term winners of the medical devices sector. According to our analysis, Johnson & Johnson, GE, Apple, Medtronic and Alphabet are the companies best positioned to benefit from investments in artificial intelligence, all of them recording scores of five out of five in GlobalData's Medical Devices Thematic Scorecard. Johnson & Johnson, for example, has advertised for 969 new artificial intelligence jobs from October 2020 to September 2021 and mentioned artificial intelligence in company filings 30 times. GE indicated good levels of AI investment, with the company looking for 446 new artificial intelligence jobs since October 2020 and mentioning artificial intelligence in filings 50 times. The table below shows how GlobalData analysts scored the biggest companies in the medical devices industry on their artificial intelligence performance, as well as the number of new artificial intelligence jobs, deals, patents and mentions in company reports since October 2020.

The medical device remains a crucial component in improving the quality of life. Key players in the medical technology arena are going on the AI track to invent cutting-edge devices with high precision and automation. Expectations are high as the future of healthcare delivery is poised for steady growth with AI onboard. Picture a smart sensor device that estimates the possibility of a heart attack or an imaging system that uses algorithms to spot a brain tumor – these are real-world evidence of AI medical technologies in action. Application design teams harmonizing AI technologies into medical devices made these realities.

The life sciences sector is one of the largest sectors with the number of patents filed in this area, as an increasing number of medical device companies are using AI to diagnose patients more precisely and to treat them more effectively but are often faced with challenges. Case study – Multi Award winning Creavo Medical Technologies Ltd is a UK based medical device company that is developing innovative diagnostic technologies. Operations Director Andrew Mullen will share his first had experience of using AI within their business and product developments. Including real life examples of a medical device, what they wanted to do with it and how they achieved it through use of AI. Aimed at people interested in AI or who are using it to develop their business.

Mumbai: Data scientists have begun betting on the use of machine learning, deep learning, Big Data and artificial intelligence (AI) technologies to help in the early detection of diseases and advance healthcare. Leading the way on the road to healthcare analytics are the world's five largest medical device companies--Johnson & Johnson, GE Healthcare, Siemens, Medtronic and Philips Healthcare. In the case of Dutch electronics, healthcare and lighting company, Philips NV, much of such innovative work is being done at the Philips Innovation Campus (PIC) in Bengaluru. PIC, according to the centre's chief executive Srinivas Prasad, initially started as a software centre in 1996, and has now developed into a product engineering site with a focus on delivering innovations for local and global markets. "Engineers and domain experts work on end-to-end products and solutions across the health continuum, from healthy living, to prevention, diagnosis and treatment. PIC is harnessing the power of technologies such as mobile, digital, cloud and Big Data analytics to improve patient outcomes through care coordination and patient empowerment. PIC takes pride in developing solutions to make healthcare affordable and accessible in India and other growth geographies like Africa and Indonesia," said Prasad.